<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37070982</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.</ArticleTitle><Pagination><StartPage>e0030923</StartPage><MedlinePgn>e0030923</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e00309-23</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/jvi.00309-23</ELocationID><Abstract><AbstractText>Coxsackievirus A21 (CVA21) is a naturally occurring RNA virus that, in preclinical studies and clinical trials, has demonstrated promising potential in treating a range of malignancies. Other oncolytic viruses, such as adenovirus, vesicular stomatitis virus, herpesvirus, and vaccinia virus, all can be engineered to carry one or more transgenes for various purposes, including immune modulation, virus attenuation, and induction of apoptosis of tumor cells. However, it remained unknown whether CVA21 can express therapeutic or immunomodulatory payloads due to its small size and high mutation rate. Using reverse genetics techniques, we demonstrated that a transgene encoding a truncated green fluorescent protein (GFP) of up to 141 amino acids (aa) can be successfully carried in the 5' end of the coding region. Furthermore, a chimeric virus carrying an eel fluorescent protein, UnaG (139 aa), was also made and shown to be stable, and it maintained efficient tumor cell-killing activity. Similar to other oncolytic viruses, the likelihood of delivering CVA21 by the intravenous route is low due to issues like blood absorption, neutralizing antibodies, and liver clearance. To address this problem, we designed the CVA21 cDNA under the control of a weak RNA polymerase II promoter, and subsequently, a stable cell pool in 293T cells was made by integrating the resulting CVA21 cDNA into the cell genome. We showed that the cells are viable and able to persistently generate rCVA21 <i>de novo</i>. The carrier cell approach described here may pave the way to designing new cell therapy strategies by arming with oncolytic viruses. <b>IMPORTANCE</b> As a naturally occurring virus, coxsackievirus A21 is a promising oncolytic virotherapy modality. In this study, we first used reverse genetics to determine whether A21 can stably carry transgenes and found that it could express up to 141 amino acids of foreign GFP. The chimeric virus carrying another fluorescent eel protein UnaG (139 amino acids) gene also appeared to be stable over at least 7 passages. Our results provided guidance on how to select and engineer therapeutic payloads for future A21 anticancer research. Second, the challenges of delivering oncolytic viruses by the intravenous route hamper the broader use of oncolytic viruses in the clinic. Here, we used A21 to show that cells could be engineered to stably carry and persistently release the virus by harboring the viral cDNA in the genome. The approach we presented here may pave a new way for oncolytic virus administration using cells as carriers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sam</LastName><ForeName>Miranda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Discovery Biologics, Merck &amp; Co., Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selman</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Discovery Oncology, Merck &amp; Co., Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Weilong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Scientific Informatics, Merck &amp; Co., Inc., West Point, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Jiwon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Discovery Biologics, Merck &amp; Co., Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willingham</LastName><ForeName>Aarron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Discovery Biologics, Merck &amp; Co., Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phan</LastName><ForeName>Uyen</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Discovery Oncology, Merck &amp; Co., Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Starling</LastName><ForeName>Gary C</ForeName><Initials>GC</Initials><AffiliationInfo><Affiliation>Discovery Biologics, Merck &amp; Co., Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qinshan</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-3745-9590</Identifier><AffiliationInfo><Affiliation>Discovery Biologics, Merck &amp; Co., Inc., South San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="N">Oncolytic Virotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cell therapy</Keyword><Keyword MajorTopicYN="N">coxsackievirus A21 (CVA21)</Keyword><Keyword MajorTopicYN="N">gene delivery</Keyword><Keyword MajorTopicYN="N">oncolytic virus</Keyword><Keyword MajorTopicYN="N">reverse genetics</Keyword><Keyword MajorTopicYN="N">transgene</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>18</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37070982</ArticleId><ArticleId IdType="pmc">PMC10231226</ArticleId><ArticleId IdType="doi">10.1128/jvi.00309-23</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaufman HL, Kohlhapp FJ, Zloza A. 2015. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14:642–662. doi:10.1038/nrd4663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd4663</ArticleId><ArticleId IdType="pmc">PMC7097180</ArticleId><ArticleId IdType="pubmed">26323545</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara H, Ino Y, Todo T. 2016. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci 107:1373–1379. doi:10.1111/cas.13027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13027</ArticleId><ArticleId IdType="pmc">PMC5084676</ArticleId><ArticleId IdType="pubmed">27486853</ArticleId></ArticleIdList></Reference><Reference><Citation>Aref S, Castleton AZ, Bailey K, Burt R, Dey A, Leongamornlert D, Mitchell RJ, Okasha D, Fielding AK. 2020. Type 1 interferon responses underlie tumor-selective replication of oncolytic measles virus. Mol Ther 28:1043–1055. doi:10.1016/j.ymthe.2020.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.027</ArticleId><ArticleId IdType="pmc">PMC7132605</ArticleId><ArticleId IdType="pubmed">32087150</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Wang X, Cheng P. 2020. Remodeling of tumor immune microenvironment by oncolytic viruses. Front Oncol 10:561372. doi:10.3389/fonc.2020.561372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.561372</ArticleId><ArticleId IdType="pmc">PMC7934618</ArticleId><ArticleId IdType="pubmed">33680911</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G, Shimada H, Hiroshima K, Tada Y, Suzuki N, Tagawa M. 2009. Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China. Drug Des Devel Ther 2:115–122. doi:10.2147/dddt.s3535.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/dddt.s3535</ArticleId><ArticleId IdType="pmc">PMC2761194</ArticleId><ArticleId IdType="pubmed">19920899</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman SS, Hecht JR, Chan E. 2019. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Immunotherapy 11:705–723. doi:10.2217/imt-2019-0033.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/imt-2019-0033</ArticleId><ArticleId IdType="pubmed">31045464</ArticleId></ArticleIdList></Reference><Reference><Citation>Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, Tanaka M. 2022. Intratumoral oncolytic herpes virus G47 for residual or recurrent glioblastoma: a phase 2 trial. Nat Med 28:1630–1639. doi:10.1038/s41591-022-01897-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01897-x</ArticleId><ArticleId IdType="pmc">PMC9388376</ArticleId><ArticleId IdType="pubmed">35864254</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Xie D, Yang L. 2022. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther 7:117. doi:10.1038/s41392-022-00951-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00951-x</ArticleId><ArticleId IdType="pmc">PMC8987060</ArticleId><ArticleId IdType="pubmed">35387984</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren DR, Dorahy DJ, Ingham RA, Burns GF, Barry RD. 1997. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol 71:4736–4743. doi:10.1128/JVI.71.6.4736-4743.1997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.71.6.4736-4743.1997</ArticleId><ArticleId IdType="pmc">PMC191695</ArticleId><ArticleId IdType="pubmed">9151867</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafren DR, Dorahy DJ, Thorne RF, Barry RD. 2000. Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 cell infection. J Gen Virol 81:889–894. doi:10.1099/0022-1317-81-4-889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-81-4-889</ArticleId><ArticleId IdType="pubmed">10725413</ArticleId></ArticleIdList></Reference><Reference><Citation>Skelding KA, Barry RD, Shafren DR. 2009. Systemic targeting of metastatic human breast tumor xenografts by coxsackievirus A21. Breast Cancer Res Treat 113:21–30. doi:10.1007/s10549-008-9899-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-008-9899-2</ArticleId><ArticleId IdType="pubmed">18256929</ArticleId></ArticleIdList></Reference><Reference><Citation>Skelding KA, Barry RD, Shafren DR. 2012. Enhanced oncolysis mediated by coxsackievirus A21 in combination with doxorubicin hydrochloride. Invest New Drugs 30:568–581. doi:10.1007/s10637-010-9614-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-010-9614-0</ArticleId><ArticleId IdType="pubmed">21170760</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley S, Jakes AD, Harrington K, Pandha H, Melcher A, Errington-Mais F. 2014. Applications of coxsackievirus A21 in oncology. Oncolytic Virother 3:47–55. doi:10.2147/OV.S56322.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OV.S56322</ArticleId><ArticleId IdType="pmc">PMC4918364</ArticleId><ArticleId IdType="pubmed">27512662</ArticleId></ArticleIdList></Reference><Reference><Citation>Andtbacka RHI, Curti B, Daniels GA, Hallmeyer S, Whitman ED, Lutzky J, Spitler LE, Zhou K, Bommareddy PK, Grose M, Wang M, Wu C, Kaufman HL. 2021. Clinical responses of oncolytic coxsackievirus A21 (V937) in patients with unresectable melanoma. J Clin Oncol 39:3829–3838. doi:10.1200/JCO.20.03246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.03246</ArticleId><ArticleId IdType="pubmed">34464163</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsedawy NB, Nace RA, Russell SJ, Schulze AJ. 2020. Oncolytic activity of targeted picornaviruses formulated as synthetic infectious RNA. Mol Ther Oncolytics 17:484–495. doi:10.1016/j.omto.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2020.05.003</ArticleId><ArticleId IdType="pmc">PMC7276391</ArticleId><ArticleId IdType="pubmed">32529026</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly EJ, Hadac EM, Cullen BR, Russell SJ. 2010. MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog 6:e1000820. doi:10.1371/journal.ppat.1000820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000820</ArticleId><ArticleId IdType="pmc">PMC2841627</ArticleId><ArticleId IdType="pubmed">20333250</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly EJ, Hadac EM, Greiner S, Russell SJ. 2008. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 14:1278–1283. doi:10.1038/nm.1776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1776</ArticleId><ArticleId IdType="pubmed">18953352</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C, Bator-Kelly CM, Rieder E, Chipman PR, Craig A, Kuhn RJ, Wimmer E, Rossmann MG. 2005. The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure 13:1019–1033. doi:10.1016/j.str.2005.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2005.04.011</ArticleId><ArticleId IdType="pubmed">16004874</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumagai A, Ando R, Miyatake H, Greimel P, Kobayashi T, Hirabayashi Y, Shimogori T, Miyawaki A. 2013. A bilirubin-inducible fluorescent protein from eel muscle. Cell 153:1602–1611. doi:10.1016/j.cell.2013.05.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.038</ArticleId><ArticleId IdType="pubmed">23768684</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon J, Park JS, Kang M, Choi S, Park J, Kim GT, Lee C, Cha S, Rhee HW, Shim SH. 2020. Bright ligand-activatable fluorescent protein for high-quality multicolor live-cell super-resolution microscopy. Nat Commun 11:273. doi:10.1038/s41467-019-14067-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-14067-4</ArticleId><ArticleId IdType="pmc">PMC6959352</ArticleId><ArticleId IdType="pubmed">31937765</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Carlisle R. 2019. Achieving systemic delivery of oncolytic viruses. Expert Opin Drug Deliv 16:607–620. doi:10.1080/17425247.2019.1617269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425247.2019.1617269</ArticleId><ArticleId IdType="pubmed">31144549</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Ibanez AR, Upadhaya S, Partridge T, Shah M, Correa D, Campbell J. 2022. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov 21:631–632. doi:10.1038/d41573-022-00095-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-022-00095-1</ArticleId><ArticleId IdType="pubmed">35650421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yim TJ, Tang S, Andino R. 1996. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice. Virology 218:61–70. doi:10.1006/viro.1996.0166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1996.0166</ArticleId><ArticleId IdType="pubmed">8615042</ArticleId></ArticleIdList></Reference><Reference><Citation>Andino R, Silvera D, Suggett SD, Achacoso PL, Miller CJ, Baltimore D, Feinberg MB. 1994. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 265:1448–1451. doi:10.1126/science.8073288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8073288</ArticleId><ArticleId IdType="pubmed">8073288</ArticleId></ArticleIdList></Reference><Reference><Citation>Teterina NL, Levenson EA, Ehrenfeld E. 2010. Viable polioviruses that encode 2A proteins with fluorescent protein tags. J Virol 84:1477–1488. doi:10.1128/JVI.01578-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01578-09</ArticleId><ArticleId IdType="pmc">PMC2812313</ArticleId><ArticleId IdType="pubmed">19939919</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Tee HK, Lee MH, Sam IC, Chan YF. 2016. Enterovirus A71 DNA-launched infectious clone as a robust reverse genetic tool. PLoS One 11:e0162771. doi:10.1371/journal.pone.0162771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0162771</ArticleId><ArticleId IdType="pmc">PMC5019408</ArticleId><ArticleId IdType="pubmed">27617744</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman NM, Kim KS, Tracy S, Jackson J, Hofling K, Leser JS, Malone J, Kolbeck P. 2000. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. J Virol 74:7952–7962. doi:10.1128/jvi.74.17.7952-7962.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.74.17.7952-7962.2000</ArticleId><ArticleId IdType="pmc">PMC112326</ArticleId><ArticleId IdType="pubmed">10933703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim BK, Shin JO, Lee SC, Kim DK, Choi DJ, Choe SC, Knowlton KU, Jeon ES. 2005. Long-term cardiac gene expression using a coxsackieviral vector. J Mol Cell Cardiol 38:745–751. doi:10.1016/j.yjmcc.2005.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2005.02.018</ArticleId><ArticleId IdType="pubmed">15850568</ArticleId></ArticleIdList></Reference><Reference><Citation>Henke A, Zell R, Ehrlich G, Stelzner A. 2001. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis. J Virol 75:8187–8194. doi:10.1128/jvi.75.17.8187-8194.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.75.17.8187-8194.2001</ArticleId><ArticleId IdType="pmc">PMC115063</ArticleId><ArticleId IdType="pubmed">11483764</ArticleId></ArticleIdList></Reference><Reference><Citation>Seago J, Juleff N, Moffat K, Berryman S, Christie JM, Charleston B, Jackson T. 2013. An infectious recombinant foot-and-mouth disease virus expressing a fluorescent marker protein. J Gen Virol 94:1517–1527. doi:10.1099/vir.0.052308-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.052308-0</ArticleId><ArticleId IdType="pmc">PMC3709630</ArticleId><ArticleId IdType="pubmed">23559477</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard MR, Cohen L, Lemon SM, Martin A. 2001. Characterization of recombinant hepatitis A virus genomes containing exogenous sequences at the 2A/2B junction. J Virol 75:1414–1426. doi:10.1128/JVI.75.3.1414-1426.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.3.1414-1426.2001</ArticleId><ArticleId IdType="pmc">PMC114048</ArticleId><ArticleId IdType="pubmed">11152515</ArticleId></ArticleIdList></Reference><Reference><Citation>Poirier JT, Reddy PS, Idamakanti N, Li SS, Stump KL, Burroughs KD, Hallenbeck PL, Rudin CM. 2012. Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001. J Gen Virol 93:2606–2613. doi:10.1099/vir.0.046011-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.046011-0</ArticleId><ArticleId IdType="pubmed">22971818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert MS, Sharp PA. 2010. Emerging roles for natural microRNA sponges. Curr Biol 20:R858–R861. doi:10.1016/j.cub.2010.08.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cub.2010.08.052</ArticleId><ArticleId IdType="pmc">PMC4070712</ArticleId><ArticleId IdType="pubmed">20937476</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert MS, Neilson JR, Sharp PA. 2007. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4:721–726. doi:10.1038/nmeth1079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth1079</ArticleId><ArticleId IdType="pmc">PMC3857099</ArticleId><ArticleId IdType="pubmed">17694064</ArticleId></ArticleIdList></Reference><Reference><Citation>Paquette JS, Fortin JF, Blanchard L, Tremblay MJ. 1998. Level of ICAM-1 surface expression on virus producer cells influences both the amount of virion-bound host ICAM-1 and human immunodeficiency virus type 1 infectivity. J Virol 72:9329–9336. doi:10.1128/JVI.72.11.9329-9336.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.72.11.9329-9336.1998</ArticleId><ArticleId IdType="pmc">PMC110356</ArticleId><ArticleId IdType="pubmed">9765484</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Salas E, Francisco-Velilla R, Fernandez-Chamorro J, Embarek AM. 2017. Insights into structural and mechanistic features of viral IRES elements. Front Microbiol 8:2629. doi:10.3389/fmicb.2017.02629.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02629</ArticleId><ArticleId IdType="pmc">PMC5759354</ArticleId><ArticleId IdType="pubmed">29354113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lulla V, Dinan AM, Hosmillo M, Chaudhry Y, Sherry L, Irigoyen N, Nayak KM, Stonehouse NJ, Zilbauer M, Goodfellow I, Firth AE. 2019. An upstream protein-coding region in enteroviruses modulates virus infection in gut epithelial cells. Nat Microbiol 4:280–292. doi:10.1038/s41564-018-0297-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0297-1</ArticleId><ArticleId IdType="pmc">PMC6443042</ArticleId><ArticleId IdType="pubmed">30478287</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata MA, Goncalves-Carneiro D, Zang TM, Soll SJ, York A, Blanco-Melo D, Bieniasz PD. 2017. CG dinucleotide suppression enables antiviral defence targeting non-self RNA. Nature 550:124–127. doi:10.1038/nature24039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24039</ArticleId><ArticleId IdType="pmc">PMC6592701</ArticleId><ArticleId IdType="pubmed">28953888</ArticleId></ArticleIdList></Reference><Reference><Citation>Rima BK, McFerran NV. 1997. Dinucleotide and stop codon frequencies in single-stranded RNA viruses. J Gen Virol 78:2859–2870. doi:10.1099/0022-1317-78-11-2859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-11-2859</ArticleId><ArticleId IdType="pubmed">9367373</ArticleId></ArticleIdList></Reference><Reference><Citation>Podshivalova ES, Semkina AS, Kravchenko DS, Frolova EI, Chumakov SP. 2021. Efficient delivery of oncolytic enterovirus by carrier cell line NK-92. Mol Ther Oncolytics 21:110–118. doi:10.1016/j.omto.2021.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2021.03.013</ArticleId><ArticleId IdType="pmc">PMC8065264</ArticleId><ArticleId IdType="pubmed">33981827</ArticleId></ArticleIdList></Reference><Reference><Citation>Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC, Kumthekar P, Lukas RV, Grimm SA, Adams AK, Hebert CD, Strong TV, Amidei C, Arrieta VA, Zannikou M, Horbinski C, Zhang H, Burdett KB, Curiel DT, Sachdev S, Aboody KS, Stupp R, Lesniak MS. 2021. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial. Lancet Oncol 22:1103–1114. doi:10.1016/S1470-2045(21)00245-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00245-X</ArticleId><ArticleId IdType="pmc">PMC8328944</ArticleId><ArticleId IdType="pubmed">34214495</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabtree GR, Olson EN. 2002. NFAT signaling: choreographing the social lives of cells. Cell 109(Suppl 1):S67–S79. doi:10.1016/s0092-8674(02)00699-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0092-8674(02)00699-2</ArticleId><ArticleId IdType="pubmed">11983154</ArticleId></ArticleIdList></Reference><Reference><Citation>Taniguchi K, Karin M. 2018. NF-kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 18:309–324. doi:10.1038/nri.2017.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.142</ArticleId><ArticleId IdType="pubmed">29379212</ArticleId></ArticleIdList></Reference><Reference><Citation>Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA. 2016. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164:770–779. doi:10.1016/j.cell.2016.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.01.011</ArticleId><ArticleId IdType="pmc">PMC4752902</ArticleId><ArticleId IdType="pubmed">26830879</ArticleId></ArticleIdList></Reference><Reference><Citation>Barta T, Peskova L, Hampl A. 2016. miRNAsong: a web-based tool for generation and testing of miRNA sponge constructs in silico. Sci Rep 6:36625. doi:10.1038/srep36625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep36625</ArticleId><ArticleId IdType="pmc">PMC5114684</ArticleId><ArticleId IdType="pubmed">27857164</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes DD, Bamrah J, Kailasam S, Gomes GW, Li Y, Wieden HJ, Gradinaru CC. 2017. Characterization of fluorescein arsenical hairpin (FlAsH) as a probe for single-molecule fluorescence spectroscopy. Sci Rep 7:13063. doi:10.1038/s41598-017-13427-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-13427-8</ArticleId><ArticleId IdType="pmc">PMC5638890</ArticleId><ArticleId IdType="pubmed">29026195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>